(SENS) Senseonics Holdings - Ratings and Ratios

Senseonics Holdings, Inc., a medical technology company, specializes in the development and manufacturing of continuous glucose monitoring (CGM) systems designed to improve diabetes management. The companys flagship products, Eversense, Eversense XL, and Eversense E3, are implantable CGM systems that measure glucose levels through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a user-friendly app for real-time monitoring and data management. These systems are differentiated by their extended wear times, with Eversense XL offering up to 180 days of continuous use, and Eversense E3 designed for 60 days, catering to different patient preferences and clinical needs.

Founded in 1996 and headquartered in Germantown, Maryland, Senseonics has established itself as a pioneer in the CGM space, particularly with its focus on implantable technology. The company distributes its products through a network of healthcare providers, distributors, and strategic partners, ensuring access to patients globally. Senseonics technology integrates advanced sensor design, proprietary fluorescence-based chemistry, and mobile health software, providing users with accurate and reliable glucose data to manage their diabetes effectively.

Ticker Symbol: SENS Exchange: NYSE MKT Type: common stock Country Origin: United States GICS Sub Industry: Health Care Supplies

Average Volume 20d: 9,866,596 Last Price: 0.83 SMA 20: 1.02 SMA 50: 0.81 SMA 200: 0.49 ATR: 0.12

Market Cap: 495.31M USD P/E: 0.00 P/E Forward: 21.51 P/B: 340.53 P/S: 22.31 RoE: 467.55

3-Month Forecast: Based on , SENS is currently trading below its 20-day and 50-day SMA, indicating bearish momentum in the short term. The stocks ATR of 0.12 suggests moderate volatility, with potential downside targets at $0.60 and $0.40 if the downtrend continues. However, if the stock rebounds off support levels, a potential upside target of $1.20 could be achievable. From a perspective, the companys high P/B ratio of 340.53 raises concerns about valuations, while the forward P/E of 21.51 reflects expectations of future profitability. The companys ability to improve margins and reduce operating losses will be critical in the near term.